» Articles » PMID: 26170984

Prognostic Value of the Expression of Phosphatase and Tensin Homolog and CD44 in Elderly Patients with Refractory Acute Myeloid Leukemia

Overview
Journal Oncol Lett
Specialty Oncology
Date 2015 Jul 15
PMID 26170984
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The leukemic stem cell marker CD44, has been reported to have prognostic significance in hematological malignancies. The present study therefore aimed to evaluate whether the expression levels of CD44 and the associated pathway components are associated with the survival rate of elderly patients with refractory acute myeloid leukemia (AML). A total of 20 elderly patients diagnosed with refractory AML were divided into two groups, following induction chemotherapy: Complete remission (CR, n=9) and non-remission (NR. n=11). Bone marrow biopsy specimens were collected, expression levels of CD44, phosphatase and tensin homolog (PTEN), mammalian target of rapamycin (mTOR) and nuclear factor-κB (NF-κB) were analyzed by immunohistochemistry and the captured images were analyzed in a blinded manner using Image Pro Plus software, version 6.0. The overall survival rates (OS) of the patients were then analyzed with log rank, and the correlation between CD44, PTEN, mTOR and NF-κB expression levels and patients survival rates were statistically analyzed using Pearson's method. Significant differences were observed between the CR and NR groups for PTEN (P=0.025) and CD44 (P=0.020) expression levels. Positive CD44 expression was significantly correlated with poor overall survival, with a hazard ratio of 6.281 (95% CI, 1.78-22.12; P=0.0042). The mean OS was 4.00 months for patients that demonstrated positive CD44 expression, compared with 9.27 months for patients that demonstrated negative CD44 expression. A tendency towards reduced survival rates was also observed in patients negative for PTEN expression, when compared with that of PTEN-positive patients. The mean OS was 4.81 months in PTEN-negative patients vs. 8.8 months in PTEN-positive patients, with a hazard ratio of 2.689 (95%CI, 0.89-8.08; P=0.078). Patients that exhibited PTEN-positive and CD44-negative expression, survived significantly longer than patients that demonstrated PTEN-negative and CD44-positive expression (mean OS, 9.86 vs 2.67 months; hazard ratio=0.037; 95% CI, 0.006-0.222, P=0.0006). The expression levels of NF-κB and mTOR were slightly increased in the NR group compared with those of the CR group, although no significant differences were identified. PTEN and CD44 expression levels demonstrated trends towards negative correlation. In conclusion, the expression levels of CD44 and PTEN may be useful markers to predict the prognosis of elderly patients with refractory AML.

Citing Articles

The roles of phosphorylation of signaling proteins in the prognosis of acute myeloid leukemia.

Marton A, Veres K, Erdodi F, Udvardy M, Illes A, Rejto L Pathol Oncol Res. 2024; 30:1611747.

PMID: 39035053 PMC: 11257863. DOI: 10.3389/pore.2024.1611747.


CD44: a cancer stem cell marker and therapeutic target in leukemia treatment.

Wu S, Tan Y, Li F, Han Y, Zhang S, Lin X Front Immunol. 2024; 15:1354992.

PMID: 38736891 PMC: 11082360. DOI: 10.3389/fimmu.2024.1354992.


PRL2 inhibition elevates PTEN protein and ameliorates progression of acute myeloid leukemia.

Carlock C, Bai Y, Paige-Hood A, Li Q, Nguele Meke F, Zhang Z JCI Insight. 2023; 8(19).

PMID: 37665633 PMC: 10619439. DOI: 10.1172/jci.insight.170065.


Radiolabeled Dendrimer Coated Nanoparticles for Radionuclide Imaging and Therapy: A Systematic Review.

Conte M, De Feo M, Sidrak M, Corica F, Gorica J, Filippi L Pharmaceutics. 2023; 15(3).

PMID: 36986728 PMC: 10051715. DOI: 10.3390/pharmaceutics15030867.


Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.

Walcher L, Kistenmacher A, Suo H, Kitte R, Dluczek S, Strauss A Front Immunol. 2020; 11:1280.

PMID: 32849491 PMC: 7426526. DOI: 10.3389/fimmu.2020.01280.


References
1.
Jordan C . The leukemic stem cell. Best Pract Res Clin Haematol. 2007; 20(1):13-8. PMC: 1988840. DOI: 10.1016/j.beha.2006.10.005. View

2.
. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

3.
Chu T, Chan H, Kuo H, Liu L, Hu T, Sun C . Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN. Oncotarget. 2014; 5(6):1475-90. PMC: 4039225. DOI: 10.18632/oncotarget.1745. View

4.
Bennett J, Catovsky D, Daniel M, Flandrin G, GALTON D, Gralnick H . Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med. 1985; 103(3):460-2. DOI: 10.7326/0003-4819-103-3-460. View

5.
Spaeth E, Labaff A, Toole B, Klopp A, Andreeff M, Marini F . Mesenchymal CD44 expression contributes to the acquisition of an activated fibroblast phenotype via TWIST activation in the tumor microenvironment. Cancer Res. 2013; 73(17):5347-59. PMC: 3767181. DOI: 10.1158/0008-5472.CAN-13-0087. View